logo
Plus   Neg
Share
Email

Lilly Reports Positive Results From Taltz 5-yr Study - Quick Facts

Eli Lilly and Company (LLY) said the results from a five-year Phase 3 study for Taltz (ixekizumab) demonstrated that patients with moderate- to severe plaque psoriasis taking Taltz can achieve sustained skin clearance over the five-year treatment period. No unexpected safety outcomes were reported, the company said.

Later in the year, Eli Lilly plans to announce the results from IXORA-R, a clinical trial designed to evaluate superiority between Taltz and Tremfya (guselkumab) in adult patients with moderate- to severe plaque psoriasis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Auto giant General Motors' (GM) Chevrolet unveiled its new stunning Corvette Stingray 2020. Stingray 2020, the eighth generation of the Chevrolet Corvette, has received the biggest change since its initial launch in 1953. The new 2020 Corvette is a mid-engine vehicle, which is its engine is behind... Amazon.com's Prime Day has brought a smile to the face of some photographers who may have grabbed their best deals of their lives. The e-commerce giant accidentally discounted a wide range of premium camera gear for Prime Day earlier this week, which may have proved costly for it. Thanks to a pricing error, some lucky customers were able to buy premium camera gear bundles for below $100. Women's clothing chain Dress Barn Inc. said it started store-closing or inventory clearance event sales at the 53 stores it plans to close by the end of August. The company expects to close all its stories by end of 2019. It also released a list of the nine stores closing in July and the stores closing in August. Dressbarn has hired Gordon Brothers Retail Partners to help with the store closures.
Follow RTT